Amgen Partners With Daiichi-Sankyo For Denosumab In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal includes regulatory milestone payments to Daiichi in exchange for use of Japanese firm’s intellectual property applicable to Amgen’s bone loss therapy.